scholarly journals Escape from homeostasis: spinal microcircuits and progression of amyotrophic lateral sclerosis

2018 ◽  
Vol 119 (5) ◽  
pp. 1782-1794 ◽  
Author(s):  
Robert M. Brownstone ◽  
Camille Lancelin

In amyotrophic lateral sclerosis (ALS), loss of motoneuron function leads to weakness and, ultimately, respiratory failure and death. Regardless of the initial pathogenic factors, motoneuron loss follows a specific pattern: the largest α-motoneurons die before smaller α-motoneurons, and γ-motoneurons are spared. In this article, we examine how homeostatic responses to this orderly progression could lead to local microcircuit dysfunction that in turn propagates motoneuron dysfunction and death. We first review motoneuron diversity and the principle of α-γ coactivation and then discuss two specific spinal motoneuron microcircuits: those involving proprioceptive afferents and those involving Renshaw cells. Next, we propose that the overall homeostatic response of the nervous system is aimed at maintaining force output. Thus motoneuron degeneration would lead to an increase in inputs to motoneurons, and, because of the pattern of neuronal degeneration, would result in an imbalance in local microcircuit activity that would overwhelm initial homeostatic responses. We suggest that this activity would ultimately lead to excitotoxicity of motoneurons, which would hasten the progression of disease. Finally, we propose that should this be the case, new therapies targeted toward microcircuit dysfunction could slow the course of ALS.

Cells ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 1449
Author(s):  
Cyril Quessada ◽  
Alexandra Bouscary ◽  
Frédérique René ◽  
Cristiana Valle ◽  
Alberto Ferri ◽  
...  

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive and selective loss of motor neurons, amyotrophy and skeletal muscle paralysis usually leading to death due to respiratory failure. While generally considered an intrinsic motor neuron disease, data obtained in recent years, including our own, suggest that motor neuron protection is not sufficient to counter the disease. The dismantling of the neuromuscular junction is closely linked to chronic energy deficit found throughout the body. Metabolic (hypermetabolism and dyslipidemia) and mitochondrial alterations described in patients and murine models of ALS are associated with the development and progression of disease pathology and they appear long before motor neurons die. It is clear that these metabolic changes participate in the pathology of the disease. In this review, we summarize these changes seen throughout the course of the disease, and the subsequent impact of glucose–fatty acid oxidation imbalance on disease progression. We also highlight studies that show that correcting this loss of metabolic flexibility should now be considered a major goal for the treatment of ALS.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4065-4065
Author(s):  
Corrado Tarella ◽  
Mario Melazzini ◽  
Mario Petrini ◽  
Giuseppe Leone ◽  
Rosanna Scime’ ◽  
...  

Abstract Background. Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder of the adult life, characterized by the progressive loss of cortical and spinal motor neurons and an outcome usually fatal within 3 to 5 yrs, due to respiratory failure, with no effective therapies presently available. Efforts are needed in ALS to find novel treatments, able to reduce or block neuronal loss and/or to rebuild damaged neuronal circuits. Recent studies have raised the interest for the use of bone marrow-derived cells (BMCs) to repair damaged nervous system; this approach seems particularly attractive in ALS, which is characterized by neuronal degeneration. Aims of the study. To evaluate, at the multicenter setting, feasibility, safety and tolerability, and possible benefit of repeated procedures of G-CSF-induced BMC mobilization in ALS patients. Patients and methods. Seven Neurology Centers, along with seven Hematology Centers, are participating to the multicenter “STEMALS” trial, that started in June 2006 and will enrol a total of 28 patients, with 4 mobilization procedures for each patients; this is the interim analysis, after 42 mobilization procedures performed on a total of 22 patients. Patient median age is 56 yrs (range 40–64), 14 are male. The protocol includes four cycles of G-CSF, scheduled at 3 mos. intervals. In each cycle, G-CSF is administered at the dose of 5 μg/kg s.c., twice a day, for 4 consecutive days. At each cycle, CBCs and circulating CD34+ cells are determined, since day 0 through day 6. Results. Overall, 18 patients completed the first G-CSF cycle and all displayed good response; peak values were for WBCs: 41 x103/μL (range 24– 71) at day 3, and for CD34+ve cells: 52/μL (range 8.4–156), at day 4; 16 patients have already completed the second mobilization course, with values of circulating cells matching those of the first cycle (median WBCs/μL: 42x103; median CD34+ve/μL: 60.7); a few patients have undergone the third and fourth cycle, again they consistently displayed high levels of mobilization. Overall, the mobilization procedures were well tolerated, with the exception of a transient increase of growth hormone level in one patient, and a deep venous thrombosis in one patient, both complications did not preclude to conclude the treatment. Conclusion. The STEMALS trial indicate that: i. the use of G-CSF to induce BMC mobilization is safe, well tolerated and feasible in ALS, even at the multicenter level; ii. so far, few and reversible adverse effects have been recorded; iii. peak values of circulating CD34+ve cells indicate that BMC mobilization capacity in ALS is analogous to that commonly observed in the healthy population; iv. there are no signs of impaired mobilization, after repeated courses of G-CSF administration, performed at few month intervals. A longer follow up is still required to verify possible benefits of the repeated BMC mobilization program in ALS.


Author(s):  
Andrew Eisen ◽  
Donald Calne

ABSTRACT:Features common to amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD) and Alzheimer’s disease (AD) are reviewed. Shared epidemiological aspects include an increasing frequency which is proportional for each disease. We draw attention to geographic non-uniform distribution which, for ALS and PD, correlates positively with latitude. Clinical and pathological overlap occurs in the same patients, and in members of the same family. A high early morning plasma cysteine/sulphate ratio possibly related to the development of proteinacious inclusions, as well as ubiquinated neuronal inclusions, characterize ALS, PD and AD. HLA-DR (the human group II major histocompatibility class) staining is marked in ALS, PD and AD and may represent autoimmunity-incited by-products of neuronal degeneration. Based upon demonstrated glutaminergic connections between the neocortex and anterior horn cells, the entorhinal cortex and the basal ganglia we hypothesize that ALS, AD and PD are phylogenetic disturbances of the neocortical cell. The postsynaptic neuron may degenerate secondarily to anterograde effects of deranged glutamate metabolism. Future therapeutic strategies should be directed to agents that decrease transmission induced by excitatory amino-acids.


Diagnostics ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 1546
Author(s):  
Hee Ra Park ◽  
Eun Jin Yang

Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) and Lou Gehrig’s disease, is characterized by a loss of the lower motor neurons in the spinal cord and the upper motor neurons in the cerebral cortex. Due to the complex and multifactorial nature of the various risk factors and mechanisms that are related to motor neuronal degeneration, the pathological mechanisms of ALS are not fully understood. Oxidative stress is one of the known causes of ALS pathogenesis. This has been observed in patients as well as in cellular and animal models, and is known to induce mitochondrial dysfunction and the loss of motor neurons. Numerous therapeutic agents have been developed to inhibit oxidative stress and neuroinflammation. In this review, we describe the role of oxidative stress in ALS pathogenesis, and discuss several anti-inflammatory and anti-oxidative agents as potential therapeutics for ALS. Although oxidative stress and antioxidant fields are meaningful approaches to delay disease progression and prolong the survival in ALS, it is necessary to investigate various animal models or humans with different subtypes of sporadic and familial ALS.


Sign in / Sign up

Export Citation Format

Share Document